AEON Biopharma(AEON) - 2024 Q2 - Quarterly Results

Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with FDA in 3Q 2024 – – 351(k) regulatory pathway offers potential to bring ABP-450 to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeut ...